Ipratropiumbromide 40 Cyclocaps Teva (Ipratropium Bromide)

Ipratropium bromide is a competitive antagonist of muscarinic (M3) receptors on airway smooth muscle and submucosal glands. By blocking acetylcholine binding, it prevents bronchoconstriction and decreases secretions, leading to bronchodilation and improved airflow in the lungs.

The prescribed dose is determined by the treating physician based on the patient’s clinical condition, disease severity, and response to therapy. The prescriber selects the number of capsules per administration and the frequency, typically ranging from one to two inhalations several times daily.

Safety data in pregnancy and lactation are limited; the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative is the long‑acting muscarinic antagonist tiotropium, which offers once‑daily dosing and a longer duration of action. Ipratropium provides short‑acting relief, typically administered multiple times per day, and may be combined with β2‑agonists for additive bronchodilation. Choice depends on disease severity, dosing convenience and clinical response.

Store at below 25 °C in the original sealed packaging, protected from moisture and direct sunlight. Keep capsules in a dry place and avoid exposure to high humidity. Do not refrigerate or freeze. Follow any additional handling instructions provided by the supplier.

The capsule is placed into a compatible dry‑powder inhaler device, pierced, and the patient inhales the released powder through the mouthpiece with a steady, deep breath. Proper technique—including a full exhalation before inhalation and a brief breath‑hold after—maximizes drug delivery to the lungs.

Serious but rare adverse events include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, angioedema, and urinary retention or worsening glaucoma in susceptible individuals. Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, or visual disturbances.

Ipratropiumbromide 40 Cyclocaps should be avoided in patients with known hypersensitivity to ipratropium bromide or any excipients, and in individuals with narrow‑angle glaucoma or urinary retention where anticholinergic effects could exacerbate the condition. Contraindications should be confirmed by a healthcare professional before initiation.